New strategy aims to tame harsh side effects of advanced lung cancer treatment
NCT ID NCT05663866
Summary
This study is testing three different medications to see if they can prevent or lessen severe reactions that some patients experience during their first infusion of a targeted lung cancer drug called amivantamab. It involves 68 adults with a specific type of advanced lung cancer that has worsened after standard treatments. The goal is to make this effective cancer therapy safer and more tolerable for patients from the very first dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
CHU Rouen Hopital Charles Nicolle
Rouen, 76000, France
-
CHU de Brest - Hopital de la Cavale Blanche
Brest, 29200, France
-
Centre Leon Berard
Lyon, 69008, France
-
Changhua Christian Hospital
Changhua, 500, Taiwan
-
Chi-Mei Medical Center, Liouying
Tainan, 73657, Taiwan
-
Chonnam National University Hwasun Hospital
Jeollanam-do, 58128, South Korea
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Compassionate Cancer Care
Fountain Valley, California, 92708, United States
-
Gachon University Gil Medical Center
Incheon, 21565, South Korea
-
Hopital Cochin
Paris, 75014, France
-
Hopital Europeen Georges-Pompidou
Paris, 75015, France
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp Virgen de La Victoria
Málaga, 29010, Spain
-
Hosp. Clinico Univ. Lozano Blesa
Zaragoza, 50009, Spain
-
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, 15706, Spain
-
Hosp. Gral. Univ. Gregorio Maranon
Madrid, 28007, Spain
-
Hosp. Gral. Univ. Valencia
Valencia, 46014, Spain
-
Hosp. San Pedro de Alcantara
Cáceres, 10003, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Hosp. Univ. Quiron Dexeus
Barcelona, 8028, Spain
-
Hosp. Univ. Son Espases
Palma de Mallorca, 07120, Spain
-
Hosp. de Jerez de La Frontera
Jerez de la Frontera, 11407, Spain
-
Hosp. de La Santa Creu I Sant Pau
Barcelona, 08025, Spain
-
Inst. Cat. Doncologia-H Duran I Reynals
L'Hospitalet de Llobregat, 08908, Spain
-
Inst. Valenciano de Oncologia
Valencia, 46009, Spain
-
Kaohsiung Medical University Chung Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
-
National Cancer Center
Gyeonggi-do, 10408, South Korea
-
National Taiwan University Hospital
Taipei, 10043, Taiwan
-
Nouvel Hopital Civil - CHU Strasbourg
Strasbourg, 67091, France
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Medical University
Taipei, 110, Taiwan
-
Taipei Veterans General Hospital
Taipei, 112, Taiwan
-
UW Medicine Valley Medical Center
Renton, Washington, 98055, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.